This statement should be read in conjunction with the existing ATAGI clinical guidance on Japanese encephalitis vaccines. ATAGI has reviewed the evidence on the intradermal (ID) administration of Japanese encephalitis (JE) vaccines and considered the potential use of Imojev as a dose-sparing mechanism, in the context of the risk of future outbreaks, expanded eligibility in risk areas, and ongoing supply considerations.

  • Recommendation
  • Western Pacific
  • Australia
  • Japanese encephalitis